Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking. PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.
Checked against the public recordLast updated Nov 13, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 4
- Sponsor
- Lisa Sanderson Cox, PhD
- Interventions being studied
- Behavioral: smoking cessation intervention; Drug: bupropion hydrochloride; Genetic: gene expression analysis; Genetic: polymerase chain reaction; Other: counseling intervention; Other: educational intervention; Procedure: psychosocial assessment and care
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * African American who has smoked ≤ 10 cigarettes per day for ≥ 2 years AND has smoked for ≥ 25 days within the past month * Not a heavy smoker * No other forms of tobacco within the past 30 days * Must be interested in stopping smoking * No other smoker in the household enrolled in this study PATIENT CHARACTERISTICS: * Has a home address and a functioning telephone number * Not planning to move from the Kansas City metro area within the next 12 months * Not pregnant or nursing * Negative pregnancy test * No alcohol or substance abuse within the past year * Not currently drinking ≥ 14 alcoholic drinks per week * No binge drinking (5 or more drinks on one occasion) on at least two occasions within the past month * No history of seizures or head trauma * No history of bulimia or anorexia nervosa * No myocardial infarction within the past 30 days * No reported use of opiates, cocaine, or stimulants * No diabetes requiring oral hypoglycemics or insulin PRIOR CONCURRENT THERAPY: * More than 30 days since prior nicotine replacement therapy, fluoxetine, clonidine, buspirone, or doxepin * No other concurrent medication that contains bupropion hydrochloride * No concurrent psychoactive medications
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Kansas Masonic Cancer Research Institute at the University of Kansas Medical CenterKansas City, Kansas
- Swope Health CentralKansas City, Missouri
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 13, 2017. Always confirm current availability with the study team.